Univercells Technologies has introduced a platform in the NevoLine biomanufacturing product family, the Upstream platform.
The design aims to assist with upstream processing by intensifying and chaining all unit operations from inoculation to midstream processing to deliver a concentrated, clarified bulk. With the NevoLine Upstream platform, commercial scale upstream production is possible in a 3 sqm module.
The NevoLine Upstream platform was designed to address the needs of gene therapy and vaccine innovators and CDMOs for upstream viral vectors manufacturing. It builds on the proof of concept with the first NevoLine biomanufacturing platform which was designed for production of a trivalent Sabin Inactivated Polio Vaccine (sIPV). The original NevoLine sIPV platform provided the ability to deliver more than 500,000 doses per batch below €0.30 per dose, within a 10 m² equipment footprint.
The NevoLine Upstream platform accommodates all unit operations from inoculation to midstream processing within a single module and is suited for GMP, clinical and commercial manufacturing of vaccines, gene therapies and oncolytic viruses. The automated platform is suitable for multiple viral applications by combining single-use assemblies in process-specific configurations.
At the core of the platform is the scale-X nitro structured fixed-bed bioreactor, providing up to 600 m² of growth surface. Mammalian cell culture and virus production can be combined with concentration and single or multi-step clarification for intensified and continuous processes.